Close

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors Oct 23, 2023 08:00AM
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference® Oct 18, 2023 04:30PM
Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry Sep 19, 2023 07:00AM
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus Aug 7, 2023 07:00AM
Castle Biosciences Reports Second Quarter 2023 Results Aug 2, 2023 04:05PM
View Older Stories

Aug 1, 2023 07:00AM Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
Jul 19, 2023 07:00AM Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
Jul 18, 2023 07:00AM Castle Biosciences to Host Second Annual Castle Cares Charity Walk
Jul 17, 2023 07:00AM Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
Jul 7, 2023 07:51AM Castle Biosciences Inc. (CSTL) to Present New DecisionDx-SCC and DecisionDx-Melanoma Data
Jul 7, 2023 07:00AM Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
Jun 30, 2023 07:00AM Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
Jun 20, 2023 07:00AM Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 12, 2023 07:03AM Castle Biosciences (CSTL) Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize
Jun 12, 2023 07:00AM Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Tradit
Jun 5, 2023 07:00AM Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational De
Jun 3, 2023 07:00AM Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
May 31, 2023 07:02AM Castle Biosciences (CSTL) Announces IDgenetix Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
May 31, 2023 07:00AM IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
May 30, 2023 07:00AM Castle Biosciences Celebrates Skin Cancer Awareness Month
May 26, 2023 07:00AM Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
May 22, 2023 07:00AM Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
May 15, 2023 07:00AM Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
May 3, 2023 04:05PM Castle Biosciences Reports First Quarter 2023 Results
May 3, 2023 07:00AM Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance
Apr 28, 2023 07:00AM Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
Apr 25, 2023 07:00AM DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
Apr 20, 2023 07:00AM TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
Apr 19, 2023 07:00AM Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
Apr 12, 2023 07:00AM Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
Mar 18, 2023 07:00AM Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Cent
Mar 14, 2023 07:00AM Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Mar 10, 2023 07:00AM Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Mar 8, 2023 07:00AM Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society f
Feb 28, 2023 04:05PM Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
Feb 24, 2023 07:00AM Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
Feb 22, 2023 07:00AM Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
Feb 9, 2023 05:00PM Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the C
Feb 7, 2023 05:00PM Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
Feb 1, 2023 05:00PM Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
Jan 23, 2023 07:00AM Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
Jan 17, 2023 05:00PM Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
Jan 9, 2023 05:04AM Castle Biosciences Inc. (CSTL) Reports Prelim Q4 Results
Jan 8, 2023 07:00PM Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
Nov 21, 2022 07:00AM Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
Nov 17, 2022 07:00AM Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
Nov 15, 2022 07:03AM Castle Biosciences (CSTL) Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx-SCC
Nov 15, 2022 07:00AM Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
Nov 14, 2022 07:00AM Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
Nov 2, 2022 04:05PM Castle Biosciences Announces Third Quarter 2022 Results
Nov 1, 2022 07:00AM Castle Biosciences to Present at Upcoming Investor Conferences
Oct 31, 2022 07:00AM Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carc
Oct 27, 2022 07:00AM Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
Oct 25, 2022 07:00AM New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus ov
Oct 24, 2022 07:04AM Castle Biosciences Inc. (CSTL) Presents New Data Demonstrating Impact of DecisionDx-SCC Test Results on Management of Medicare-Eligible Patients with cSCC and One or More Risk Factors
View Older Stories